Artes Medical Announces Appointment of Christopher J. Reinhard as Chairman of Board of Directors.SAN DIEGO San Diego (săn dēā`gō), city (1990 pop. 1,110,549), seat of San Diego co., S Calif., on San Diego Bay; inc. 1850. San Diego includes the unincorporated communities of La Jolla and Spring Valley. Coronado is across the bay. -- Artes Medical Inc., a privately-held specialty pharmaceutical and medical device company, today announced the appointment of Christopher J. Reinhard as Chairman of the Board of Directors. Reinhard, co-founder and Chief Executive Officer of Collateral Therapeutics, joins the existing board members as they direct Artes toward the commercialization of its lead product ArteFill, the first permanent injectable in·ject·a·ble adj. Capable of being injected. Used of a drug. n. A drug or medicine that can be injected. wrinkle filler to successfully complete U.S. FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. clinical trials. Artes Medical recently received an approvable letter from the FDA for ArteFill. "We are proud to have Chris Reinhard joining our organization as we accelerate into the commercialization phase of ArteFill. Chris' expertise will be invaluable as we prepare for a worldwide market launch early next year and an exit strategy for our investors," commented Dr. Stefan M. Lemperle, M.D., co-founder and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Artes Medical. Reinhard brings ten years of biotechnology executive leadership to the Artes Medical Board. In 1995, Reinhard co-founded Collateral Therapeutics, a San Diego-based biotechnology company utilizing technology licensed from the University of California, San Diego UCSD is consistently ranked among the top ten public universities for undergraduate education in the United States by U.S. News & World Report.[3] It is a Public Ivy. [1] For graduate studies, most of UCSD's Ph.D. to develop non-surgical cardiovascular gene therapeutics. Reinhard steered Collateral through a strategic partnership with pharmaceutical company Schering AG and an initial public offering in 1998. When Collateral successfully completed early clinical studies and was acquired by Schering AG in 2002, Reinhard became the company's Chief Executive Officer. Prior to founding Collateral, Reinhard was a merchant banking and venture investment executive and an executive officer of the Henley Group, Fisher Scientific and Imed Corporation. Reinhard received a B.S. and MBA MBA abbr. Master of Business Administration Noun 1. MBA - a master's degree in business Master in Business, Master in Business Administration from Babson College. "Artes Medical has made significant advances in the development of its proprietary technology platform. I look forward to building on this success as we establish the company's new San Diego GMP GMP (guanosine monophosphate): see guanine. manufacturing facility and bring the company's lead product ArteFill to market. With an aging population, interest in new and innovative personal aesthetics products continues to rapidly expand. Our strategy to secure U.S. regulatory approval for ArteFill as a permanent injectable dermal dermal /der·mal/ (der´mal) pertaining to the dermis or to the skin. der·mal or der·mic adj. Of or relating to the skin or dermis. filler for the treatment of facial wrinkles and scars is expected to provide our patented product with strong competitive advantages in the U.S. and international markets," stated Reinhard. Artes Medical Inc. Artes Medical is a specialty pharmaceutical and medical device company focused on the development of new and innovative products for the personal aesthetics market. The company's lead product ArteFill is a unique permanent injectable dermal filler administered by company-trained Plastic Surgeons and Dermatologists for the treatment of facial wrinkles and scars. The company's product development is centered around its proprietary platform technology and formulations of injectable collagen and synthetic microspheres, which have potentially wide ranging applications as permanent bulking agents for soft tissue augmentation. ArteFill has been developed for the personal aesthetics market. In addition, the company plans to establish strategic partnerships to commercialize the development of (1) ArteSeal to seal and restore spinal disc injuries and for other orthopaedic applications including non-surgical connective tissue repair; (2) ArteFlux as a soft tissue bulking agent for the treatment of gastro-esophageal reflux disease (GERD GERD gastroesophageal reflux disease. GERD abbr. gastroesophageal reflux disease GERD ); and (3) ArteSure for the treatment of stress urinary incontinence stress urinary incontinence n. See stress incontinence. (SUI Sui (swā), dynasty of China that ruled from 581 to 618. This short-lived dynasty reunified China in 589 after 400 years of division and laid the foundation for further consolidation under the T'ang dynasty. ). ArteFill has received an approvable letter from the FDA, following successful completion of company-sponsored U.S. clinical trials. The company is in the process of establishing a San Diego-based GMP manufacturing facility for the production of ArteFill and its portfolio of other development stage product candidates, including ArteSeal, ArteFlux and ArteSure. Artes Medical expects to begin marketing ArteFill to company-trained Plastic Surgeons and Dermatologists early next year. For more information about the company, technology platform and product development activities, visit the company's website www.artesmedical.com. Artes Medical, ArteFill, ArteSeal, ArteFlux and ArteSure are trademarks of Artes Medical, Inc. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion